Micro Medical Solutions’ Pivotal STAND Trial of MicroStent Completes Enrollment

December 6, 2023—Micro Medical Solutions (MMS), a developer of microvascular interventions for the treatment of chronic limb-threatening ischemia (CLTI), announced that it has completed enrollment in STAND, the United States pivotal trial of the company’s MicroStent peripheral vascular stent system.

The company stated that STAND is a randomized controlled trial composed of 177 patients that is evaluating the safety and effectiveness of MicroStent compared to the current standard of care (percutaneous transluminal angioplasty) in treating peripheral artery disease (PAD) below the knee. The final patient in the trial was enrolled earlier this month, marking the completion of the study.

The study’s lead investigator is Robert E. Beasley, MD, of Palm Vascular Centers in Miami Beach, Florida.

“I would like to thank the investigators and the research teams for their dedication, participation, collaboration, and tremendous effort to help this complex and difficult patient population,” commented Dr. Beasley in the company’s press release. “I’m excited to continue to provide research expertise to the company and discuss the study results when available.”

According to the company, the MicroStent vascular stent is specifically designed to achieve and maintain tibioperoneal arterial patency, improving blood flow and wound healing for below-the-knee amputation reduction in patients with CLTI resulting from progressive PAD.

The MicroStent system has obtained CE Mark approval for use in the European Economic Area.